FDA Inspection 1253398 — Takeda Pharmaceuticals, Inc.
The FDA completed an inspection of Takeda Pharmaceuticals, Inc. on October 16, 2024 in Cambridge, MA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- October 16, 2024
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Cambridge, MA (United States)
Additional Details
Risk Evaluation and Mitigation Strategies (REMS)